Liver disease induced by radioembolization of liver tumors
2008/02/07 by Bruno Sangro, Belen Gil‐Alzugaray, Belén Gil-Alzugaray +13 · 27 citations
Medicine · #Hepatocellular Carcinoma Treatment and Prognosis #Organ Transplantation Techniques and Outcomes #Liver Disease and Transplantation
paper · pdf · doi:10.1002/cncr.23339
Abstract
BACKGROUND: To the authors' knowledge, liver damage after liver radioembolization with yttrium90-labeled microspheres has never been studied specifically. METHODS: Using a complete set of data recorded prospectively among all patients without previous chronic liver disease treated by radioembolization at the authors' institution from September 2003 to July 2006, patterns of liver damage were identified and possible risk factors were analyzed. RESULTS: In all, 20% of patients developed a distinct clinical picture that appeared 4 to 8 weeks after treatment and was characterized by jaundice and ascites. Veno-occlusive disease was the histologic hallmark observed in the most severe cases. This form of sinusoidal obstruction syndrome was not observed among patients who never received chemotherapy or in those in whom a single hepatic lobe was treated. Relevant to treatment planning, a possible risk factor was a higher treatment dose in relation to the targeted liver volume. A transjugular intrahepatic stent shunt improved liver function in 2 patients with impending liver failure, although 1 of them eventually died from it. CONCLUSIONS: Radioembolization of liver tumors, particularly after antineoplastic chemotherapy, may result in an uncommon but potentially life-threatening form of hepatic sinusoidal obstruction syndrome that presents clinically with jaundice and ascites.
Cited by
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
- Radioembolization for neuroendocrine tumors: procedure, application and clinical outcomes
- Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings. [europepmc]
- Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. [europepmc]
- Research reporting standards for radioembolization of hepatic malignancies. [europepmc]
- Radioembolization for primary and metastatic liver cancer. [europepmc]
- Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. [europepmc]
- Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. [europepmc]
- Side effects of yttrium-90 radioembolization. [europepmc]
- Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. [europepmc]
- Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. [europepmc]
- Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. [europepmc]
- Quantitative Measurements of Enhancement on Preprocedure Triphasic CT Can Predict Response of Colorectal Liver Metastases to Radioembolization. [europepmc]
- Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. [europepmc]
- Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma. [europepmc]
- Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes. [europepmc]
- Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry. [europepmc]
- Additional hepatic 166 Ho-radioembolization in patients with neuroendocrine tumours treated with 177 Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). [europepmc]
- Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. [europepmc]
- Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. [europepmc]
- Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with 90 Y-Microspheres: A Systematic Review. [europepmc]
- Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design. [europepmc]
- The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. [europepmc]
- Management of patients with intermediate stage hepatocellular carcinoma. [europepmc]
- Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know. [europepmc]
- Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe. [europepmc]
- ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. [europepmc]
Related